GlassScriptPhysician profile
Amy L Ross
NPI 1710433909
$281,062.58
in general payments reported to CMS, 2019-2025
15 companies · $61K in 2025
The $61K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $93.58 · 2022: $70K · 2023: $83K · 2024: $67K · 2025: $61K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $165K · Travel and Lodging: $28K · Consulting Fee: $12K · Food and Beverage: $6,445.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $165,229.97 |
| Travel and Lodging | $27,626.00 |
| Consulting Fee | $11,985.00 |
| Food and Beverage | $6,445.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $132,076.26 | 2022-2025 | Mavenclad, Mavenclad |
| Alexion Pharmaceuticals, INC. | $113,841.36 | 2022-2025 | Ultomiris, Soliris |
| Tg Therapeutics, INC. | $21,093.81 | 2022-2025 | |
| Genzyme Corporation | $3,622.13 | 2022 | |
| Banner Life Sciences, LLC | $2,171.37 | 2022-2023 | |
| Argenx US, INC. | $2,040.49 | 2023 | Vyvgart |
| Cycle Pharmaceuticals INC | $2,004.97 | 2023 | |
| Biogen, INC. | $1,694.46 | 2022 | |
| F. Hoffmann-La Roche Ag | $1,400.00 | 2024 | |
| Mylan Specialty L.P. | $906.55 | 2023 | |
| Abbott Laboratories | $81.73 | 2021 | |
| Amgen INC. | $66.00 | 2025 | |
| Lilly USA, LLC | $27.97 | 2025 | Kisunla, Amyvid |
| Amylyx Pharmaceuticals, INC. | $23.63 | 2023 | Relyvrio |
| Biodelivery Sciences International, INC. | $11.85 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.